6 results
To prospectively test for superiority of atogepant 60 mg QD versus placebo for the prevention of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral medications for the prophylaxis of migraine
The primary objective of this study is to investigate whether electrical stimulation applied to the abdominal wall muscles in synchrony with exhalation can be feasible to prevent the development of atrophy of the abdominal wall muscles during the…
Main objective: To assess the effect of CK-2127107 versus placebo on respiratory function in patients with ALS.
The purpose of this study is to evaluate whether the new drug reldesemtiv is effective and safe in patients with ALS. The primary objective is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.The secondary objectives…
To assess the long-term safety and tolerability of reldesemtiv in patients with ALS
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).